Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Odyssey Health (ODYY) Research & Development (2021 - 2024)

Odyssey Health has reported Research & Development over the past 1 years, most recently at $1.0 million for Q3 2021.

  • For Q3 2021, Research & Development changed N/A year-over-year to $1.0 million; the TTM value through Jul 2021 reached $1.6 million, changed N/A, while the annual FY2024 figure was $55166.0, 67.55% down from the prior year.
  • Research & Development for Q3 2021 was $1.0 million at Odyssey Health, up from $565764.0 in the prior quarter.
  • Over five years, Research & Development peaked at $1.0 million in Q3 2021 and troughed at $42619.0 in Q1 2021.